Literature DB >> 11222447

Long-term remyelination after optic neuritis: A 2-year visual evoked potential and psychophysical serial study.

A Brusa1, S J Jones, G T Plant.   

Abstract

Thirty-one patients were followed-up, at 3-month intervals for the first year and at 6-month intervals for the second year, after an episode of optic neuritis. The object was to confirm previous evidence for a progressive shortening of visual evoked potential (VEP) latencies and to determine whether this is associated with any change in the clinical ocular examination, visual fields or contrast sensitivity. VEP latencies were found to decrease significantly during both the first and (less strikingly) the second year, the most marked changes occurring between 3 and 6 months. Contrast sensitivity improved during the first 9 months, but subsequently tended (non-significantly) to deteriorate. A similarly transient improvement in central visual field sensitivity was seen in a subgroup of patients with clinically overt multiple sclerosis. In the data from the acutely unaffected fellow eyes, no significant changes in VEP parameters or functional indices were observed. The findings extend those of a previous study which showed significant shortening of VEP latencies between 6 months and 3 years without significant functional improvement. Over this period, a significant prolongation of VEP latencies occurred in the asymptomatic fellow eye, accompanied by contrast sensitivity deterioration. Taken in conjunction, the two studies suggest that recovery processes involving remyelination or, possibly, ion channel reorganization proceed for at least 2 years. The concurrent effects of insidious demyelination and/or axonal degeneration (also occurring in the fellow optic nerve) are initially masked by the recovery process, but gradually become more evident. The functional benefits of the long-term recovery process are relatively minor and are usually reversed within a few years. Nevertheless, it is suggested that long-term remyelination may perform an important role in protecting demyelinated axons from degeneration. Understanding the factors which promote long-term remyelination may have significant implications for therapy in multiple sclerosis.

Entities:  

Mesh:

Year:  2001        PMID: 11222447     DOI: 10.1093/brain/124.3.468

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  42 in total

Review 1.  Neurophysiological markers.

Authors:  Letizia Leocani; Giancarlo Comi
Journal:  Neurol Sci       Date:  2008-09       Impact factor: 3.307

2.  Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis.

Authors:  R T Naismith; N T Tutlam; J Xu; J B Shepherd; E C Klawiter; S-K Song; A H Cross
Journal:  Neurology       Date:  2009-07-07       Impact factor: 9.910

3.  Dissecting structure-function interactions in acute optic neuritis to investigate neuroplasticity.

Authors:  Thomas Jenkins; Olga Ciccarelli; Ahmed Toosy; Katherine Miszkiel; Claudia Wheeler-Kingshott; Daniel Altmann; Laura Mancini; Steve Jones; Gordon Plant; David Miller; Alan Thompson
Journal:  Hum Brain Mapp       Date:  2010-02       Impact factor: 5.038

4.  Independent patterns of damage to retinocortical pathways in multiple sclerosis without a previous episode of optic neuritis.

Authors:  Aldina Reis; Catarina Mateus; M Carmo Macário; José R Faria de Abreu; Miguel Castelo-Branco
Journal:  J Neurol       Date:  2011-03-31       Impact factor: 4.849

5.  New developments in the treatment of optic neuritis.

Authors:  Thomas M Jenkins; Ahmed T Toosy
Journal:  Eye Brain       Date:  2010-06-17

6.  How Common Is Signal-Intensity Increase in Optic Nerve Segments on 3D Double Inversion Recovery Sequences in Visually Asymptomatic Patients with Multiple Sclerosis?

Authors:  T Sartoretti; E Sartoretti; S Rauch; C Binkert; M Wyss; D Czell; S Sartoretti-Schefer
Journal:  AJNR Am J Neuroradiol       Date:  2017-06-29       Impact factor: 3.825

7.  Evoked potentials as a biomarker of remyelination.

Authors:  Moones Heidari; Abigail B Radcliff; Gillian J McLellan; James N Ver Hoeve; Kore Chan; Julie A Kiland; Nicholas S Keuler; Benjamin K August; Dylan Sebo; Aaron S Field; Ian D Duncan
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-16       Impact factor: 11.205

Review 8.  Achievements and obstacles of remyelinating therapies in multiple sclerosis.

Authors:  Martin Stangel; Tanja Kuhlmann; Paul M Matthews; Trevor J Kilpatrick
Journal:  Nat Rev Neurol       Date:  2017-11-17       Impact factor: 42.937

9.  Assessing visual pathway function in multiple sclerosis patients with multifocal visual evoked potentials.

Authors:  Michal Laron; Han Cheng; Bin Zhang; Jade S Schiffman; Rosa A Tang; Laura J Frishman
Journal:  Mult Scler       Date:  2009-12-07       Impact factor: 6.312

Review 10.  Visual electrophysiology in the clinical evaluation of optic neuritis, chiasmal tumours, achiasmia, and ocular albinism: an overview.

Authors:  Jelka Brecelj
Journal:  Doc Ophthalmol       Date:  2014-06-25       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.